Search clinical trials for: Trametinib tablets

Total 6840 results

Tasly Pharmaceutical Group Co., Ltd

Completed

Study of Jitongning Tablet to Treat Spondyloarthritis

Spondyloarthritis

China
GlaxoSmithKline

Withdrawn

A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors

Solid Tumours
GlaxoSmithKline

Completed

A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers

Cancer

Japan
GlaxoSmithKline

Completed

Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation

Cancer

United States
Stanford University
Boston Children's Hospital

Recruiting

Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation

Arterial Disease | Venous Malformation

United States
University Health Network, Toronto

Not yet recruiting

Pilot Study on Trametinib for Surgical Unruptured AVMs (OZUHN-017)

Arteriovenous Malformations
Yiling Pharmaceutical Inc.

Completed

A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease

China
The National Institutes of Pharmaceutical R&D Co...

Completed

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

Idiopathic Pulmonary Fibrosis

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

Nonalcoholic Steatohepatitis (NASH)

China
Atridia Pty Ltd.

Completed

A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect.

Inflammatory Bowel Disease

Australia
Lexicon Pharmaceuticals

Completed

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Harmony Biosciences, LLC

Active, not recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Prader-Willi Syndrome

United States
Melanoma Institute Australia
Novartis

Recruiting

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

Melanoma

Australia
Dong Wha Pharmaceutical Co. Ltd.

Completed

The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

Diabetic Kidney Disease

Korea, Republic of
Paratek Pharmaceuticals Inc

Active, not recruiting

Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)

Mycobacterium Infections, Nontuberculous | Nontuberculous Mycobacterial Lung Disease | Mycobacterium Abscessus Infection | Nontuberculous Mycobacterial Pulmonary Infection

United States
Rigshospitalet, Denmark

Completed

The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.

Hyponatremia | Metabolic Bone Disease

Denmark
Sinew Pharma Inc.

Completed

Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers

Nonalcoholic Steatohepatitis

Taiwan
Memorial Sloan Kettering Cancer Center

Completed

Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | KRAS Gene Mutation

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Clinical Pharmacology Trial of Brexpiprazole Once-weekly (QW) Formulation Administered as Single and Multiple Oral Doses

Schizophrenia

Japan
Valenta Pharm JSC

Recruiting

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Cholecystitis

Russian Federation
Fulcrum Therapeutics

Completed

Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets

Healthy Adult Subjects

United States
Overseas Pharmaceuticals, Ltd.
GX pharma technology (beijing) Co., Ltd

Active, not recruiting

An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions.

Partial Seizure

China
GlaxoSmithKline

Withdrawn

A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors

Cancer
Vaxart

Completed

Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)

Respiratory Syncytial Virus (RSV)

United States
Beijing Tiantan Hospital
NeuroDawn Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Sarecycline in Patients With Acute Ischemic Stroke After Reperfusion Therapy (ESPRIT)

Ischemic Stroke, Acute

China
Damanhour University

Completed

Ivabradine in Patients With Congestive Heart Failure

Congestive Heart Failure

Egypt
The Netherlands Cancer Institute
GlaxoSmithKline

Unknown

Lapatinib Plus Trametinib in KRAS Mutant NSCLC (M14LTK)

Colorectal Cancer

Netherlands
University of California, Los Angeles

Recruiting

Metformin Treatment in Progressive Multiple Sclerosis

Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
Ultragenyx Pharmaceutical Inc

Completed

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

Hereditary Inclusion Body Myopathy (HIBM)

United States
Shanghai Henlius Biotech

Recruiting

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Solid Tumor

China
Vaxart

Completed

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines (VXA-NVV-103)

Norovirus Infection

United States
Dana-Farber Cancer Institute
Novartis; National Comprehensive Cancer Network

Terminated

GSK1120212+GSK2141795 for Cervical Cancer

Cervical Cancer

United States
Universitair Ziekenhuis Brussel

Completed

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

Malignant Melanoma

Belgium
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations

Unresectable Melanoma | Stage IV Melanoma | Stage III Melanoma | BRAF Mutant Melanoma

United States
Adil Daud
National Comprehensive Cancer Network

Completed

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Melanoma

United States
Stallergenes Greer

Completed

Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma

Asthma | House Dust Mite Allergy

France, Germany, Poland
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

Gastric Cancer | Metaplasia | Stage I Gastric Cancer | Initial-onset Gastric Cancer

Japan
Jonsson Comprehensive Cancer Center
Novartis

No longer available

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Progressive Metastatic Castrate Resistant Prostate Cancer
Asan Medical Center

Unknown

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Cancer | Lung Cancer Metastatic | BRAF V600E

Korea, Republic of
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
Leiden University Medical Center
Novartis

Recruiting

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study) (NEO-ATACT)

Anaplastic Thyroid Cancer

Netherlands
Bayer

Completed

Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers

Pharmacokinetics

Germany
Novartis Pharmaceuticals

Completed

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

Malignant Melanoma

Portugal
Novartis Pharmaceuticals

Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor

Japan
University Hospital, Essen

Recruiting

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI)

Metastatic Thyroid Cancer

Germany
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand
Sun Yat-sen University

Not yet recruiting

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

NSCLC | BRAF V600 Mutation | MET Exon 14 Mutation

China
Genfit

Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma

Cholangiocarcinoma

United States, Puerto Rico
Novartis Pharmaceuticals

Recruiting

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (LEAD Melanoma)

Melanoma

Turkey
Novartis Pharmaceuticals

Recruiting

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Melanoma

China

3

Subscribe